India

Serum Institute of India restarts manufacturing of Covishield

He said the company already has six million booster doses of the Covovax vaccine available and adults must take the booster shot.

New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Wednesday said it has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.

He said the company already has six million booster doses of the Covovax vaccine available and adults must take the booster shot.

Reacting to reports of COVID-19 vaccines shortage, he said manufacturers are ready but there has been no demand.

“Just as a precaution, at risk we have done it so that people have a Covishield as a choice if they want it,” Poonawalla told PTI on restarting of manufacturing of the vaccine.

The company had stopped manufacturing of Covishield in December 2021.

On Covovax which has been approved as a booster dose for 18-years and above, he said, “We have six million doses ready but the demand is exactly zero.”

Covovax booster is now on the CoWin app, he said.

This post was last modified on April 12, 2023 5:13 pm

Share
Press Trust of India

Press Trust of India (PTI) is India’s premier news agency, having a reach as vast as the Indian Railways. It employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.

Load more...